Iobenguane
- Generic Name
- Iobenguane
- Brand Names
- Azedra
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10IN3
- CAS Number
- 80663-95-2
- Unique Ingredient Identifier
- 35MRW7B4AD
- Background
Synthetic guanethidine derivative that locates phaeochromocytomas and neuroblastomas. The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that metabolize noradrenaline. Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008.
- Indication
Detection of primary and metastatic pheochromocytoma or neuroblastoma
- Associated Conditions
- Metastatic Adrenal Gland Pheochromocytoma, Metastatic Neuroblastoma, Primary Neuroblastomas, Primary Pheochromocytomas, Unresectable, locally advanced iobenguane-scan positive Paraganglioma, Unresectable, locally advanced iobenguane-scan positive Pheochromocytomas, Unresectable, metastatic iobenguane-scan positive Paraganglioma, Unresectable, metastatic iobenguane-scan positive Pheochromocytomas
- Associated Therapies
- -
Perspective Therapeutics Reports $267.8M Cash Position, Advances Cancer Drug Trials
Perspective Therapeutics reported Q3 2024 financial results, with $267.8 million in cash and investments, expected to fund operations into mid-2026. Key developments include advancing [212Pb]VMT01 trials in melanoma patients and [212Pb]VMT-α-NET in neuroendocrine tumors. The company started shipping from a second manufacturing facility in Somerset, New Jersey, and purchased additional facilities in Houston, Chicago, and Los Angeles. Q3 2024 showed a net loss of $15.1 million ($0.21 per share), with research and development expenses at $12.0 million and general administrative expenses at $7.0 million.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath